Probiotics from the standpoint of evidence-based medicine

Kaibysheva V.O.; Nikonov E.L.

doi:https://doi.org/10.17116/dokgastro2019803145

Close metadata

Recommended articles:

Pharmacological treatment options for functional gastrointestinal disorders in children. Russian Journal of Evidence-Based Gastroenterology. 2025;(4):46-54

Nutrition correction in the complex therapy and rehabilitation of the posttraumatic stress disorder. Russian Journal of Preventive Medicine. 2025;(2):114-119

Clinical case of disturbance of the gut microbiota due to the use of braces-system. Russian Journal of Stomatology. 2025;(1):36-39

Monitoring of the postoperative period of dental implant placement to assess the microbiota of the periimplant sulcus. Russian Journal of Stomatology. 2025;(2):45-51

Probiotics in the treatment and prevention of vaginitis in pregnant women. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):22-26

Abstract:

The number of trials and reports devoted to probiotics is steadily increased. Effectiveness of various probiotic strains of microorganisms is reported for metabolic disorders (diabetes, dyslipidemia, obesity), gastrointestinal diseases (inflammatory bowel disease, constipation, antibiotic-associated diarrhea, Clostridium difficile-associated disease, irritable bowel syndrome), atopic diseases (food allergy, rhinitis), liver diseases (cirrhosis, non-alcoholic fatty liver disease, hepatic encephalopathy), pancreatic diseases (acute pancreatitis) and others. Administration of probiotics in clinical practice is associated with some difficulties due to a huge variety of probiotic drugs, the absence of uniform standards for their production, insufficient evidence base regarding the most effective dosages, forms of release, etc. However, specific strains of probiotics effective for each disease are currently determined with various degrees of evidence. There are recommendations regarding a differentiated approach to the selection of probiotics depending on a particular disease.

Keywords:

clostridium difficile-associated disease

irritable bowel syndrome

inflammatory bowel disease

antibiotic-associated diarrhea

probiotics

eradication therapy

Authors:

Kaibysheva V.O.

N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
City Clinical Hospital №31, Moscow, Russia

ORCID: 0000-0003-0114-3700

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

Scopus AuthorID: 57216680476
ResearcherID: T-9090-2017
ORCID: 0000-0003-3021-6534

Close metadata

References:

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology. 2014;11(8):506-514. https://doi.org/10.1038/nrgastro.2014.66
Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS ONE. 2018;13(12):e0209205. https://doi.org/10.1371/journal.pone.0209205
Grand View Research. Nutraceuticals and Functional Foods. Global Industry Report. September 2016. Accessed October 10, 2019. Available at: http://www.grandviewresearch.com/industry-analysis/probiotics-market
Draper K, Ley C, Parsonnet J. A survey of probiotic use practices among patients at a tertiary medical centre. Beneficial Microbes. 2017;8(3):345-351. https://doi.org/10.3920/BM2016.0148
Draper K, Ley C, Parsonnet J. Probiotic guidelines and physician practice: a cross-sectional survey and overview of the literature. Beneficial Microbes. 2017;8(4):507-519. https://doi.org/10.3920/BM2016.0146
Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA. Recommendations for Probiotic Use — 2015 Update: Proceedings and Consensus Opinion. Journal of Clinical Gastroenterology. 2015;49(Suppl 1):S69-S73. https://doi.org/10.1097/MCG.0000000000000420
Cruchet S, Furnes R, Maruy A, Hebel E, Palacios J, Medina F. The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American Experts. Paediatric Drugs. 2015;17(3):199-216. https://doi.org/10.1007/s40272-015-0124-6
Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. Journal of Clinical Gastroenterology. 2015;49(Supp 1):S37-S45. https://doi.org/10.1097/MCG.0000000000000349
Szajewska H, Canani RB, Guarino A, Hojsak I, Indrio F, Kolacek S, Orel R, Shamir R, Vandenplas Y, van Goudoever JB, Weizman Z; ESPGHAN Working Group for ProbioticsPrebiotics. ESPGHAN Working Group for Probiotics Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Journal of Pediatric Gastroenterology and Nutrition. 2016;62(3):495-506. https://doi.org/10.1097/MPG.0000000000001081
Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition. 2018;45:125-134.e11. https://doi.org/10.1016/j.nut.2017.06.024
Ardatskaya MD, Bel’mer SV, Dobritsa VP, Zakharenko SM, Lazebnik LB, Minushkin ON, Oreshko LS, Sitkin SI, Tkachenko EI, Suvorov AN, Khavkin AI, Shenderov BA. Colon Dysbacteriosis (Dysbiosis): Modern State Of The Problem, Comprehensive Diagnosis And Treatment Correction Eksperimental’naya i klinicheskaya gastroenterologiya. 2015;117(5):13-50. (In Russ.)
Microbiota. Pod red. Nikonova EL, Popovoj EL. M.: Izdatel’stvo Media Sfera; 2019. (In Russ.)
Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines, 2017. Accessed October 10, 2019. Available at: https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics
Millette M, Nguyen A, Amine KM, Lacroix M. Gastrointestinal survival of bacteria in commercial probiotic products. International Journal of Probiotics and Prebiotics. 2013;8(4):149-156.
McFarland LV, Goh S. Preventing Pediatric Antibiotic-Associated Diarrhea and Clostridium difficile Infections with Probiotics: a meta-analysis. World Journal of Meta-Analysis. 2013;1(3):102-120. https://doi.org/10.13105/wjma.v1.i3.102
Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews. 2015;12:CD004827. https://doi.org/10.1002/14651858
Ouwehand AC. A review of dose-responses of probiotics in human studies. Beneficial Microbes. 2017;8(2):143-151. https://doi.org/10.3920/BM2016.0140
Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134: e176-e191. https://doi.org/10.1542/peds.2013-3950
Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. European Journal of Gastroenterology and Hepatology. 2001;13:391-396. https://doi.org/10.1097/00042737-200104000-00015
Sanders ME, Klaenhammer TR, Ouwehand AC, Pot B, Johansen E, Heimbach JT, Marco ML, Tennilä J, Ross RP, Franz C, Pagé N, Pridmore RD, Leyer G, Salminen S, Charbonneau D, Call E, Lenoir-Wijnkoop I. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Annals of the New York Academy of Sciences. 2014;1309:1-18. https://doi.org/10.1111/nyas.12363
Doron S, Snydman DR. Risk and safety of probiotics. Clinical Infectious Diseases. 2015;60(Supple 2):S129-S134. https://doi.org/10.1093/cid/civ085
Sanders ME, Akkermans LM, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, Phothirath P, Solano-Aguilar G, Vaughan E. Safety assessment of probiotics for human use. Gut Microbes. 2010;1:164-185. https://doi.org/10.4161/gmic.1.3.12127
Vaarala O. Immunological effects of probiotics with special reference to lactobacilli. Clinical and Experimental Allergy. 2003;33:1634-1640. https://doi.org/10.1111/j.1365-2222.2003.01835.x
Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Stoen R, Klingenberg C. Bifidobacterium longum Subspecies infantis Bacteremia in 3 Extremely Preterm Infants Receiving Probiotics. Emerging Infectious Diseases. 2016;22(9):1664-1666. https://doi.org/10.3201/eid2209.160033
Klein G, Hallmann C, Casas IA, Abad J, Louwers J, Reuter G. Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods. Journal of Applied Microbiology. 2000;89:815-824. https://doi.org/10.1046/j.1365-2672.2000.01187.x
Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, Low DE, Goldstein EJ. Is primary prevention of Clostridium difficile infection possible with specific probiotics? International Journal of Infectious Diseases. 2012;16(11):e786-792. https://doi.org/10.1016/j.ijid.2012.06.005
McFarland LV. An observation on inappropriate probiotic sub-group classifications in the meta-analysis by Lau and Chamberlain. International Journal of General Medicine. 2016;9:333-336. https://doi.org/10.2147/IJGM.S119970
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients. American Journal of Gastroenterology. 2010;105(7):1636-1641. https://doi.org/10.1038/ajg.2010.11
Maziade PJ, Pereira P, Goldstein EJC. A decade of experience in primary prevention of C. difficile infection at a community hospital using the probiotic combination L. acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2 (BioK+). Clin Infect Dis. 2015;60(Suppl 2): S144-S147. https://doi.org/10.1093/cid/civ178
McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. Journal of Hospital Infection. 2018;99(4):443-452. https://doi.org/10.1016/j.jhin.2018.04.017
Trick WE, Sokalski SJ, Johnson S, Bunnell KL, Levato J, Ray MJ, Weinstein RA. Effectiveness of Probiotic for Primary Prevention of Clostridium difficile Infection: A Single-Center Before-and-After Quality Improvement Intervention at a Tertiary-Care Medical Center. Infection Control and Hospital Epidemiology. 2018;39(7):765-770. https://doi.org/10.1017/ice.2018.76
Evans CT, Safdar N. Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clinical Infectious Diseases. 2015;60(Suppl 2):S66-S71. https://doi.org/10.1093/cid/civ140
McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. Journal of the American Medical Association. 1994;271(24):1913-1918.
Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW. The search for a better treatment for recurrent Clostridium difficile disease: the use of high dose vancomycin combined with Saccharomyces boulardii. Clinical Infectious Diseases. 2000;31(4):1012-1017. https://doi.org/10.1086/318130
Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. American Journal of Gastroenterology. 2000;95(S1):S11-S13.
Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. Journal of Medical Microbiology. 2005;54:905-906. https://doi.org/10.1099/jmm.0.46096-0
McFarland LV, Malfertheiner P, Huang Y, Wang L. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World Journal of Metaanalysis. 2015;3(2):97-117. https://doi.org/10.13105/wjma.v3.i2.97
McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Journal of Gastroenterology. 2016;4(4):546-561. https://doi.org/10.1177/2050640615617358
Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G, Castellazzi AM. Using probiotics in clinical practice: where are we now? A review of existing metaanalyses. Gut Microbes. 2017;8(6):521-543. https://doi.org/10.1080/19490976.2017.1345414
Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Møller PL, Michaelsen KF, Paerregaard A, Sandström B, Tvede M, Jakobsen M. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Applied and Environmental Microbiology. 1999;65(11):4949-4956.
Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421(6921):384-388. https://doi.org/10.1038/nature01339
Segawa S, Fujiya M, Konishi H, Ueno N, Kobayashi N, Shigyo T, Kohgo Y. Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One. 2011;6(8):e23278. https://doi.org/10.1371/journal.pone.0023278
Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World Journal of Gastroenterology. 2014;20(26):8709-8716. https://doi.org/10.3748/wjg.v20.i26.8709
Grandy G, Medina M, Soria R, Tera ́n CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infectious Diseases. 2010;10:253. https://doi.org/10.1186/1471-2334-10-253
Szajewska H, Ruszczyński M, Kolaček S. Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatrica. 2014;103(3):249-255. https://doi.org/10.1111/apa.12487